H2020Индивидуална стипендия2018–2020

NanoFEITH · Nanoparticles for Fluorescence-Enhanced Imaging and Therapy of Breast Cancer

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2018-06-01 → 2020-09-13
Финансиране от ЕС: 151 649 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Наноструктури се разработват за едновременно откриване чрез флуоресцентно изображение и лечение на трипломно негативен рак на гърдата. Това е важно, за да се осигури по-точна диагностика и по-безопасно лечение с по-малко странични ефекти за пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Nanoparticles for Fluorescence-Enhanced Imaging and Therapy of Breast Cancer

Despite significant medical advances, breast cancer (BC) remains a leading cause of cancer-related death in women worldwide, with approximately 2.1 million cases reported each year worldwide. Triple negative breast cancers (TNBCs) represent around 15-20% of BC tumors and do not express any predictive / therapeutic biological markers. Therefore, for TNBCs, non-targeted chemotherapy is the only treatment option, and although most patients initially respond well to this treatment, most of them relapse with distant metastases. Consequently, there is an imminent need to develop novel targeted strategies for the diagnosis and treatment of TNBC. Nanotechnology offers new promise in mitigating TNBC mortality, through the possibility of combining precise early-stage TNBC diagnosis with more effective and safe treatments, in the same nanostructured device (termed theranostic). The aim of this project was to apply a multidisciplinary approach in order to develop and evaluate a novel multifunctional theranostic nanostructure, which would be able to combine ultra-sensitive fluorescence imaging of TNBC tumours with multimodal cancer treatment. This project may offer new possibilities for cancer detection, prevention, and treatment. The approach used here, based on fluorescence imaging in the near-infrared wavelength range, promises to enable real-time specific imaging that minimizes the harmful side effects of diagnostic/therapeutic methods used in current practice. The insights provided through this project may be highly transferable to the clinic, with the potential to benefit the quality of life of patients with BC, which is a leading cause of death among women. Novel treatment methods for aggressive BC also have the potential to reduce the burden of healthcare systems in Europe and worldwide, accompanied by financial benefits. The development and evaluation of the multifunctional nanoparticles explored in this project may also provide new opportunities for on-demand therapy and pave the way toward a new era of personalized nanomedicine. The overall objective of the project was to synthesize nano-engineered particles based on gold (Au) nanobipyramids (AuNBPs) that dramatically improve imaging sensitivity and pave the way for novel high-performance diagnostic devices. Meanwhile, targeted chemotherapeutic drug delivery is integrated in the proposed nanostructures, aiming to optimize drug delivery to tumours and reduce harmful effects to healthy tissues, as well as making the nanostructures suitable for image-guided therapy.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Breast cancer (BC) represents a leading cause of cancer-related death in women worldwide, in large part due to ineffective detection and treatment. Nanotechnology offers new promise in mitigating BC mortality, by combining therapy with early diagnosis in “theranostic” nanoparticles (NPs). Here, a multidisciplinary approach is proposed to develop and evaluate novel theranostic NPs, which for the first time combine near infrared (NIR) metal-enhanced fluorescence (MEF) imaging with multimodal cancer treatment. MEF is a promising strategy for dramatically improving the low fluorescent signals of available NIR dyes, but limited MEF platforms for in vivo applications have been developed. Here, elongated gold (Au) NPs (nanobipyramids) with two sharp tips and tunable sizes/optical properties are expected to provide distinct advantages, including large fluorescence enhancement and increased tumour accumulation, thus enabling real-time in vivo imaging with high sensitivity and spatial resolution. Furthermore, BC photothermal therapy by the Au core will be combined with a chemotherapeutic drug-carrier surface coating, bearing pH-responsive lids to allow controlled drug and Zn ion release at the tumour site. Coordinated use of these modalities is expected to minimize systemic side effects, improve therapeutic efficacy and be useful in treating drug resistant tumours. Several complementary techniques, including computational modelling, 3D in vitro cell cultures, in vivo testing and advanced 3D imaging will be combined to characterize NP biodistribution, biocompatibility and passive vs. active tumour targeting. These will provide vital insights for the – still challenging – clinical translation of NPs in general, paving the way toward personalized nanomedicine. The proposed research/training will complement the Applicant’s skills in materials science with the Host’s expertise in cancer drug delivery to enhance his professional maturity and promote international collaborations.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITY OF CYPRUS · NicosiaКоординаторКипър